NewsRx

Search our medical news database

Cancer Vaccines

Systemic IL-12 Boosts Effect of IL-2 Producing Cancer Vaccine

Published in Vaccine Weekly, March 11th, 1996

The systemic administration of interleukin 12 (IL-12) boosts the curative effect of a cancer vaccine engineered to release IL-2.

When genes for cytokines, like IL-12 and IL-2, are transduced in tumor cells they stimulate an efficient antitumor reaction which involves both nonspecific and specific immune mechanisms that impairs the oncogenicity of the engineered cells. When used as a vaccine, these cells are capable of eliciting an immune memory which inhibits subsequent tumor challenge.

Unfortunately, when tackling established tumors, the effect of cytokine tumor vaccines lacks enough punch to cure a well-established cancer. However, of all the...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook